Lung Cancer

A221504 (NCT03087708)

A Randomized, Double-Blind, Placebo-Controlled Pilot of Naloxegol (an Oral, Selective Peripheral Opioid Receptor Antagonist) in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)

---

NRG LU002 (NCT03137771)

Maintenance systemic therapy versus consolidative sterotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer: A randomized phases II/III trial.

---

NRG CC003 (NCT02635009)

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

---

ECOG E4512 (NCT02201992) – Must have Consented to ALCHEMIST A151216 Trial

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

---

A081105 (NCT02193282) – Must have Consented to ALCHEMIST A151216 Trial

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

---

A151216 (NCT02194738) ALCHEMIST (suspended for pts w/squamous histology effective 8/26/19)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

---

MATCH: EAY131 (NCT02465050)

MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.

---